Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and ...
Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations failing primary endpoints despite improved safety, underscoring unmet need ...
The Phase III study FIND-CKD ( NCT05047263) — investigating the efficacy and safety of KERENDIA ® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...
Bayer announces finerenone meets primary endpoint in pivotal phase III FIND-CKD study in patients with non-diabetic chronic kidney disease: Berlin Tuesday, March 17, 2026, 15:00 H ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
A new study links AKI recovery thresholds to long-term kidney failure and mortality risk. Discover why a 10% creatinine recovery matters.
Barclays 28th Annual Global Healthcare Conference March 11, 2026 1:30 PM EDTCompany ParticipantsAnthony Pagano - Executive VP ...
BioAtla has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend ...
Findings from the FIND-CKD trial indicate finerenone may provide a new treatment option for slowing renal function loss in CKD patients without diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results